To include your compound in the COVID-19 Resource Center, submit it here.

Afinitor everolimus regulatory update

FDA's Oncologic Drugs Advisory Committee (ODAC) voted 10-0 that Novartis' Afinitor

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE